3-Amino-pyrrolidine-1-carboxylic acid benzyl ester trifluoroacetate | 185057-51-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Amino-pyrrolidine-1-carboxylic acid benzyl ester trifluoroacetate
• 英文别名: 3-aminopyrrolidine-1-carboxylic acid benzyl ester trifluoroacetate；1-Cbz-3-aminopyrrolidine trifluoroacetate；benzyl 3-aminopyrrolidine-1-carboxylate;2,2,2-trifluoroacetic acid
• CAS: 185057-51-6
• 化学式: C₂HF₃O₂*C₁₂H₁₆N₂O₂
• 分子量: 334.295
• InChiKey: QXXNCKIWCBPZIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-Amino-pyrrolidine-1-carboxylic acid benzyl ester trifluoroacetate 、 氯甲酸丁酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 3-butoxycarbonylamino-pyrrolidine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  [EN] HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS
  [FR] PYRAZOLE-CARBOXAMIDES HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2Y12

  摘要：

  公开号：

  WO2009080226A3
• 作为产物：
  描述：

  benzyl 3-((tert-butoxycarbonyl)amino)pyrrolidine-1-carboxylate 、 三氟乙酸 以 苯甲醚 为溶剂， 反应 0.33h， 生成 3-Amino-pyrrolidine-1-carboxylic acid benzyl ester trifluoroacetate
  参考文献：
  名称：

  Antithrombotic agents

  摘要：

  本申请涉及到公式I的化合物（或其前药或其药学上可接受的盐或前药），如本文所定义，以及其药物组合物，以及其作为因子Xa抑制剂的用途，以及其制备方法和中间体。

  公开号：

  US20040010017A1

文献信息

• Amidopyrazole Derivative
  申请人：Kanaya Naoaki

  公开号：US20070219210A1

  公开（公告）日：2007-09-20

  A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar 1 and Ar 2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxy carbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

  提供了一种血小板凝血抑制剂，它既不抑制COX-1也不抑制COX-2。该抑制剂是由通式（I）表示的化合物：其中Ar1和Ar2独立地表示一个5-或6-成员的芳香杂环基团，可选地取代1至3个取代基，或一个苯基，可选地取代1至3个取代基；R1表示较低的酰基，羧基，较低的烷氧羰基，较低的烷氧基，较低的烷基，可选地取代1或2个取代基的氨基甲酰基，可选地取代1或2个取代基的草酰基，可选地取代1或2个取代基的氧代草酰基，可选地取代1或2个取代基的氨基，可选地取代1或2个取代基的4-至7-成员脂环杂环基团，可选地取代1或2个取代基的苯基，或可选地取代1至3个取代基的5-或6-成员芳香杂环基团；R2表示氢原子，卤素基或类似物。
• HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20110021537A1

  公开（公告）日：2011-01-27

  The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R1；R2；Z；A；B；D；Q；J；V；G和M具有所述声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，因此具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常适用于存在不希望的血小板ADP受体P2Y12激活的情况，或者用于治疗或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制剂。
• AMIDOPYRAZOLE DERIVATIVE
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1698626A1

  公开（公告）日：2006-09-06

  A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

  提供了一种既不抑制 COX-1 也不抑制 COX-2 的血小板凝固抑制剂。该抑制剂为通式 (I) 所代表的化合物： 其中 Ar1 和 Ar2 独立地代表任选被 1 至 3 个取代基取代的 5 或 6 元芳香杂环基团，或任选被 1 至 3 个取代基取代的苯基；R1 代表低级酰基、羧基、低级烷氧羰基、低级烷氧基、任选被 1 或 2 个取代基取代的低级烷基、任选被 1 或 2 个取代基取代的氨基甲酰基、任选被 1 或 2 个取代基取代的草酰基、任选被 1 或 2 个取代基取代的氨基，任选被 1 或 2 个取代基取代的 4 至 7 元脂环杂环基团，任选被 1 至 3 个取代基取代的苯基，或任选被 1 至 3 个取代基取代的 5 或 6 元芳香杂环基团；R2 代表氢原子、卤素基团或类似物。
• EP1698626
  申请人：——

  公开号：——

  公开（公告）日：——
• DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE
  申请人：PFIZER INC.

  公开号：EP0828754A1

  公开（公告）日：1998-03-18